SEARCH

SEARCH BY CITATION

References

  • 1
    Carmichael ST. Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx 2005;2:396409.
  • 2
    Pereira MP, Hurtado O, Cardenas A et al. Rosiglitazone and 15-deoxy-delta(12,14)-prostaglandin J(2) cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab 2006;26:21829.
  • 3
    Wang CX, Yang T, Shuaib A. An improved version of embolic model of brain ischemic injury in the rat. J Neurosci Methods 2001;109:14751.
  • 4
    Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 2004;1:10110.
  • 5
    Gerriets T, Stolz E, Walberer M, Kaps M, Bachmann G, Fisher M. Neuroprotective effects of MK-801 in different rat stroke models for permanent middle cerebral artery occlusion. Stroke 2003;34:22349.
  • 6
    Suzuki Y, Takagi Y, Nakamura R, Hashimoto K, Umemura K. Ability of NMDA and non-NMDA receptor antagonists to inhibit cerebral ischemic damage in aged rats. Brain Res 2003;964:11620.
  • 7
    Stevenson RW, McPherson RK, Genereux PE, Danbury BH, Kreutter DK. Antidiabetic agent englitazone enhances insulin action in nondiabetic rats without producing hypoglycemia. Metabolism 1991;40:126874.
  • 8
    Fujiwara T, Okuno A, Yoshioka S, Horikoshi H. Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism 1995;44:48690.
  • 9
    Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002;34:21724.
  • 10
    Yue T, Chen J, Bao W et al. In vivo myocardial protection from ischemia/reperfusin injury by the peroxisome prolifrator-activated receptor-γ agonist reosiglitazone. Circulation 2002;104:258894.
  • 11
    Sundarajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE. Peroxisome proliferator-activated receptor-γ ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 2005;130:68596.
  • 12
    Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci 2003;100:67127.
  • 13
    Culmsee C, Junker V, Kremers W, Thal S, Plesnila N, Krieglstein J. Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol. Stroke 2004;35:1197202.
  • 14
    Shuaib A, Wang CX, Yang T, Noor R. Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model. Stroke 2002;33:30337.
  • 15
    Zhang RL, Chopp M, Zhang ZG, Jiang Q, Ewing JR. A rat model of focal embolic cerebral ischemia. Brain Res 1997;766:8392.
  • 16
    Asahi M, Huang Z, Thomas S, Yoshimura S, Sumii T, Mori T. Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J Cereb Blood Flow Metab 2005;25:7229.
  • 17
    Dinapoli VA, Rosen CL, Nagamine T, Crocco T. Selective MCA occlusion: a precise embolic stroke model. J Neurosci Methods 2006;154:2338.
  • 18
    Wang CX, Todd KG, Yang Y, Gordon T, Shuaib A. Patency of cerebral microvessels after focal embolic stroke in the rat. J Cereb Blood Flow Metab 2001;21:41321.
  • 19
    Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion evaluation of the model and development of a neurologic examination. Stroke 1986;17:4726.
  • 20
    Franowicz JS, Arnsten AF. Actions of alpha-2 noradrenergic agonists on spatial working memory and blood pressure in rhesus monkeys appear to be mediated by the same receptor subtype. Psychopharmacology (Berl) 2002;162:30412.
  • 21
    Racine RJ. Modification of seizure activity by electrical stimulation II Motor seizure. Electroencephalogr Clin Neurophysiol 1972;32:28194.
  • 22
    Chakrabarti R, Vikramadithyan RK, Kumar MP, Kumar SK, Mamidi NV, Misra P. PMT13 a pyrimidone analogue of thiazolidinedione improves insulin resistance-associated disorders in animal models of type 2 diabetes. Diabetes Obes Metab 2002;4:31928.
  • 23
    Allahtavakoli M, Shabanzadeh AP, Sadr SS, Parviz M, Djahanguiri B. Rosiglitazone a peroxisome proliferator-activated receptor-γ ligand reduces infarction volume and nurological deficits in an embolic model of stroke. Clin Exp Pharmacol Physiol 2006;33:10528.
  • 24
    Begon S, Pickering G, Eschalier A, Dubray C. Magnesium and MK-801 have a similar effect in two experimental models of neuropathic pain. Brain Res 2000;887:4369.
  • 25
    Church J, Zeman S, Lodge D. The neuroprotective action of ketamine and MK-801 after transient cerebral ischemia in rats. Anesthesiology 1988;69:7029.
  • 26
    Lyden PD, Jackson-Friedman C, Shin C, Hassid S. Synergistic combinatorial stroke therapy: a quantal bioassay of a GABA agonist and a glutamate antagonist. Exp Neurol 2000;163:47789.
  • 27
    Lee J, Reding M. Effect of thiazolidinediones on stroke recovery: a case-matched cntrolled study. Neurochem Res 2007;32:6358.
  • 28
    Bordet R, Ouk T, Petrault O et al. PPAR a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 2006;34:13416.
  • 29
    Sundarajan S, Landreth GE. Antiinflammatory properties of PPARγ agonists following ischemia. Drug News Perspect 2004;17:22935.
  • 30
    Aoun P, Watson DG, Simpkins JW. Neuroprotective effects of PPARgamma agonists against oxidative insults in HT-22 cells. Eur J Pharmacol 2003;472:6571.
  • 31
    Heneka MT, Klockgether T, Feinstein DL. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 2000;20:68627.
  • 32
    Uryu S, Harada J, Hisamoto M, Oda T. Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebral granule neurons. Brain Res 2002;924:22936.
  • 33
    Barth AL, Newell DW. Combination therapy with MK-801 and a-phenyl-tert-butyl-nitrone enhances protection against ischemic neuronal damage in organotypic hippocampal slice cultures. Exp Neurol 1998;141:3306.
  • 34
    Parker JC. Troglitazone, the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus. Adv Drug Deliv Rev 2002;54:117397.